Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

Wake Network Is Laser Focused On Advancing Fungi-Based Medicine Through Cutting Edge Technology and Clinical Research

Oct 16, 2020 • 8:12 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

A few months ago, we highlighted Wake Network as a psychedelic therapy company that we consider to be a leading play on an emerging industry and want to provide an update on the opportunity.

Wake Network is laser focused on advancing fungi and plant-based medicine by leveraging clinical research, wellness professionals, and technology. The company has developed a regenerative feedback loop that allows it to research, monitor and incorporate results from clinical studies to personalize medicine to reduce the level of ambiguous results from traditional medicine.

A Differentiated Growth Story

The psychedelic therapy company has been able to differentiate itself from competitors by executing on a Jamaica based joint venture and by attracting strategic human capital to the leadership team.

Wake Jamaica is a separate division of the business and is a cultivation-focused joint venture subsidiary that is managed by Pauline Smith and her group of mycologists and farmers. Earlier this year, Wake opened a facility offers psilocybin-based therapy on a 3,000-acre mountain retreat, private beach and pavilion in Jamaica. At the facility, licensed professionals assess patients and track biofeedback.

In the psychedelic therapy industry, human capital is one of the most important aspects of any company. When we are analyzing a psychedelic therapy business, we spend time analyzing the leadership team and are most favorable on the businesses that are led by executives that have previously worked in the pharmaceutical industry and that have experience with the Food and Drug Administration (FDA) clinical trial process.

In regards to the leadership team, we are excited about the value that Dr. Olga Chernoloz adds to the business as the Director of Psychedelic Research.. Dr. Chernoloz is a specialist in the pharmacology of psychoactive compounds and is a trained neuropharmacologist and a registered pharmacist.

Dr. Chernoloz provides scientific advisory to companies in cannabinoid and psychedelic space. She is a scientific advisor to The Toronto Centre for Psychedelic Science and is interested in the therapeutic potential of cannabinoids and psychedelic drugs in the treatment of mental health disorders. We are favorable on Dr. Chernoloz’s background and expect her to play an important role in the advancement of the business.

We believe that Wake Network represents an attractive play on the psychedelic therapy market and has significant potential catalysts for growth. The company is privately held, and we expect it to complete a go-public transaction in the near future. If you are interested in learning Wake Network, please send an email to support@technical420.com with the subject “Wake Network” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link